Litigation Details for Novartis Pharmaceuticals Corporation v. HEC Pharm Co., Ltd. (D. Del. 2020)

« Back to Dashboard

Novartis Pharmaceuticals Corporation v. HEC Pharm Co., Ltd. (D. Del. 2020)

Docket		Date Filed	2020-01-27
Court	District Court, D. Delaware	Date Terminated
Cause	35:1 Patent Infringement	Assigned To	Leonard Philip Stark
Jury Demand	None	Referred To
Patents	10,543,179; 9,187,405
Link to Docket	External link to docket

Details for Novartis Pharmaceuticals Corporation v. HEC Pharm Co., Ltd. (D. Del. 2020)

Date Filed	Document No.	Description	Snippet	Link To Document
2020-01-27	234	Opinion - Memorandum Opinion	infringement of U.S. Patent No. 10,543,179 ("the '179 patent"). The '179 patent relates to…quot;It is a bedrock principle of patent law that the claims of a patent define the invention to which…quot;A claim in a patent provides the metes and bounds of the right which the patent confers on the patentee…that inform patent law." Id. The ultimate question of the proper construction of a patent is a question…x27;s construction of U.S. Patent No. 9,187,405 ("the '405 patent") in Novartis Pharmaceuticals	External link to document

Novartis v. HEC Pharm Co., Ltd. (1:20-cv-00133-GBW): Litigation Summary, Claims at Issue, and Exposure Analysis

Last updated: June 23, 2026

Novartis Pharmaceuticals Corporation v. HEC Pharm Co., Ltd., case 1:20-cv-00133-GBW (D. Del.), centers on a branded drug portfolio dispute in which Novartis sought to stop HEC Pharm’s FDA pathway from turning into an infringing commercial launch. The litigation posture at a “district-court only” level is what matters for business and IP planning: whether the court issued a liability decision, what patents were adjudicated, and whether any settlement or licensing agreement was reached that effectively sets the timing of generic entry.

What patents are asserted in 1:20-cv-00133-GBW?
No complete patent-identification set is available in the provided input. Without the asserted patent numbers and the specific counts (direct infringement, induced infringement, declaratory relief, prosecution-history estoppel, etc.), a complete infringement and validity analysis cannot be produced.

What is the procedural status of 1:20-cv-00133-GBW?
No docket outcomes are included in the provided input. Without docket events (complaint filing, amendment, responsive pleadings, claim construction, summary judgment, trial dates, Rule 41 dismissals, consent judgments, settlement orders, appellate filings), a reliable status and exposure assessment cannot be produced.

Key licensing and launch risk from the case?
No Orange Book, Paragraph IV status, settlement terms, or entry date details are included in the provided input. Without those, the case cannot be mapped to exclusivity windows, design-around pathways, or generic/biosimilar launch scenarios.

Because the request is for a litigation summary and analysis, the response must include hard data on asserted patents, litigation events, and outcomes. The provided input contains only the caption and docket number, which is insufficient to produce an accurate, complete litigation report.

Key Takeaways

• A litigation summary requires asserted patent numbers, claims at issue, and docket outcomes. Those facts are not present in the provided input.
• A business-grade exposure analysis requires linkage to FDA submissions and Paragraph IV/settlement timelines. Those are not present in the provided input.
• No further detail can be generated without patent identifiers and procedural history for 1:20-cv-00133-GBW.

FAQs

1. What is the asserted patent list in Novartis Pharmaceuticals Corp. v. HEC Pharm Co., Ltd., 1:20-cv-00133-GBW?
2. What stage is 1:20-cv-00133-GBW in (motions, claim construction, summary judgment, trial, settlement)?
3. Did the parties enter a settlement or consent judgment that affects generic launch timing?
4. Which FDA mechanism (ANDA, 505(b)(2), Paragraph IV) is implicated in 1:20-cv-00133-GBW?
5. What claims and remedies are typically pursued in Novartis v. generic challengers in D. Del. Hatch-Waxman suits?

References

(No sources were provided in the prompt.)